FRAXA Ewsearch OrganisationIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
Tag Archive for: partnership
Polpharma Biologics SAPolpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma’s vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa (MENA) region.
Solar FoodsAfter Finnish protein powder producer Solarfoods signed a strategic agreement with two US food manufacturers to supply 6,000 tonnes of Solein from 2030 onwards, the company has now announced a more concrete partnership with US flavour manufacturer Sensapure Flavours Inc.
Unnatural Products IncCalifornia oral macrocyclic peptide specialist Unnatural Products, Inc. and Dutch-Belgian Argenx SE have formed a multi-target research collaboration aimed at developing oral macrocyclic peptide drugs with UNP’s synthetic macrocycle platform.
adobe stock - aliaksandrBritish cell and gene therapy CDMO eXmoor Pharma plc, and KU Leuven which has just launched a translational cell and gene therapy hub in Belgium have inked a strategic collaboration supporting the hub’s work in four areas.
Building on the January 2025 ALS drug discovery collaboration with Alchemab Therapeutics, Eli Lilly & Company has secured rights to the first IND-ready program under a US$415m licensing agreement.
adobe stock - JHVEPhoto Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
Menarini GroupFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
wikipedia - AnypodetosLINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply.
Wuxi BiologicsNippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency.